Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Daver Naval, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Nitin Jain, MD, Gautam Borthakur, MD, Elias Jabbour, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Adam Craig, MD PhD, Farhad Ravandi, MD

Blood (2014) 124 (21): 385.

https://doi.org/10.1182/blood.V124.21.385.385

Published: 2014

Journal Articles

Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

H. Jean Khoury, MD, Jorge E. Cortes, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Michele Baccarani, MD, Dan Douer, MD, Adam Craig, MD, PhD, Hagop M. Kantarjian, MD, Luke Akard, MD

Blood (2012) 120 (21): 3753.

https://doi.org/10.1182/blood.V120.21.3753.3753

Published: 2012

Journal Articles

Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Hagop M. Kantarjian, MD, Jeffrey H. Lipton, MD, PhD, Michele Baccarani, MD, Franck E. Nicolini, MD, PhD, Meir Wetzler, MD, Luke Akard, MD, Laurence Legros, MD, PhD, Krzysztof Warzocha, Adam Craig, MD, PhD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2787.

https://doi.org/10.1182/blood.V120.21.2787.2787

Published: 2012

Journal Articles

Associations Between Baseline Mutation Status and Response to Treatment with Omacetaxine Mepesuccinate in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Jeffrey H. Lipton, MD, PhD, Franck E. Nicolini, MD, PhD, Meir Wetzler, MD, Luke Akard, MD, Michele Baccarani, MD, Hagop M. Kantarjian, MD, Adam Craig, MD, PhD, Jorge E Cortes, MD

Blood (2012) 120 (21): 4433.

https://doi.org/10.1182/blood.V120.21.4433.4433

Published: 2012

Journal Articles

Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

Jorge E. Cortes, Franck E. Nicolini, MD, PhD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Luke P. Akard, MD, Adam Craig, MD, PhD, Nisha Nanda, PhD, Carrie Dial, BS, Annie-Claude Benichou, MD, Katie Cairati, MS, Michele Baccarani, MD, Gerard T. Kennealey, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3761.

https://doi.org/10.1182/blood.V118.21.3761.3761

Published: 2011

Journal Articles

Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure

Jorge E. Cortes, MD, Meir Wetzler, MD, Jeff Lipton, MD, FRCPC, Franck E Nicolini, MD, PhD, Michele Baccarani, MD, Maria R Baer, M.D., H. Jean Khoury, David Cram, PharmD, Eric D. Humphriss, BA, Annie-Claude Benichou, MD, Adam Craig, MD, PhD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 2290.

https://doi.org/10.1182/blood.V116.21.2290.2290

Published: 2010

NARROW

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Associations Between Baseline Mutation Status and Response to Treatment with Omacetaxine Mepesuccinate in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

Long-Term Follow-up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.

Associations Between Baseline Mutation Status and Response to Treatment with Omacetaxine Mepesuccinate in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only